Sugi Predict

Sugi Predict / Compounds / SCHEMBL19599673

SCHEMBL19599673

SCHEMBL19599673

CC(C)Oc1ccc(-c2ccc(N3C(=S)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)cc2F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 1/20 0.62
▸ AR P10275 15/20 0.62
▸ GABRP O00591 1/20 0.61
▸ GABRD O14764 1/20 0.61
▸ NR1I2 O75469 1/20 0.61
▸ NR3C1 P04150 1/20 0.61
▸ PGR P06401 1/20 0.61
▸ KLK3 P07288 1/20 0.61
▸ GABRA1 P14867 1/20 0.61
▸ GABRB1 P18505 1/20 0.61
▸ GABRG2 P18507 1/20 0.61
▸ CNR1 P21554 1/20 0.61
▸ TBXA2R P21731 1/20 0.61
▸ GABRB3 P28472 1/20 0.61
▸ GABRA5 P31644 1/20 0.61
▸ GABRA3 P34903 1/20 0.61
▸ GABRA2 P47869 1/20 0.61
▸ GABRB2 P47870 1/20 0.61
▸ GABRA4 P48169 1/20 0.61
▸ GABRE P78334 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25721025 0.94 ABCG2 (0.61) ABCG2ARGABRPGABRDNR1I2
SCHEMBL17520007 0.91 ABCG2 (0.65) ABCG2ARGABRPGABRDNR1I2
SCHEMBL22006731 0.91 AR (0.71) ABCG2ARGABRPGABRDNR1I2
SCHEMBL19599576 0.90 AR (0.75) ABCG2ARGABRPGABRDNR1I2
SCHEMBL23483254 0.87 ABCG2 (0.61) ABCG2ARGABRPGABRDNR1I2
SCHEMBL17517177 0.87 AR (0.59) ABCG2ARGABRPGABRDNR1I2
SCHEMBL19599578 0.87 ABCG2 (0.68) ABCG2ARGABRPGABRDNR1I2
SCHEMBL20046794 0.86 AR (0.68) ABCG2ARGABRPGABRDNR1I2
SCHEMBL19599577 0.83 AR (0.56) ABCG2ARGABRPGABRDNR1I2
SCHEMBL18456832 0.83 ABCG2 (0.79) ABCG2ARGABRPGABRDNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352351-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2022-06-07 — — US disclosed
US-11236051-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2022-02-01 — — US disclosed
US-20210171470-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2021-06-10 — — US disclosed
US-20210040044-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2021-02-11 — — US disclosed
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2021-01-14 — — US disclosed
US-10844021-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2020-11-24 — — US disclosed
US-20200155690-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2020-05-21 — — US disclosed
US-20200055825-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR Arvinas, Inc. 2020-02-20 — — US disclosed
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2018-04-12 — — US disclosed
US-20170327469-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2017-11-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055825-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, MDM2, ESRRA ABCG2 688/4885AR 1/4885GABRP 1937/4885
US-20210040044-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN ABCG2 1034/4885AR 1/4885GABRP 1049/4885
US-20210171470-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN ABCG2 1034/4885AR 1/4885GABRP 1049/4885
US-20210009528-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN ABCG2 1009/4885AR 1/4885GABRP 1066/4885
US-20170327469-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, MDM2, ESRRA ABCG2 688/4885AR 1/4885GABRP 1937/4885
US-20180099940-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, ADRM1, CRBN ABCG2 1034/4885AR 1/4885GABRP 1049/4885
US-10844021-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN ABCG2 1034/4885AR 1/4885GABRP 1049/4885
US-20200155690-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 ABCG2 2329/4885AR 3776/4885GABRP 1305/4885
US-11236051-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ADRM1, CRBN ABCG2 1009/4885AR 1/4885GABRP 1066/4885
US-11352351-B2 Compounds and methods for the targeted degradation of androgen receptor AR, ESRRA, MDM2 ABCG2 759/4885AR 1/4885GABRP 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.